Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13538240 | 0.93 | KDM4E (0.45) | MAPTL3MBTL1HPGDMAPK1TDP1 | |
| SCHEMBL3660700 | 0.81 | KDM4E (0.50) | MAPTL3MBTL1HPGDMAPK1TDP1 | |
| SCHEMBL78925 | 0.81 | L3MBTL1 (0.45) | MAPTL3MBTL1HPGDMAPK1TDP1 | |
| SCHEMBL13538059 | 0.80 | MAPT (0.44) | MAPTL3MBTL1HPGDMAPK1TDP1 | |
| SCHEMBL1751411 | 0.78 | MAPT (0.49) | MAPTL3MBTL1HPGDMAPK1TDP1 | |
| SCHEMBL3735442 | 0.77 | MAPT (0.52) | MAPTL3MBTL1HPGDMAPK1TDP1 | |
| SCHEMBL13538060 | 0.75 | DGAT1 (0.47) | MAPTL3MBTL1HPGDMAPK1TDP1 | |
| SCHEMBL256028 | 0.75 | PIK3CD (0.43) | MAPTALDH1A1KDM4EGABRA5 | |
| SCHEMBL13538398 | 0.74 | REN (0.49) | MAPTL3MBTL1HPGDMAPK1 | |
| SCHEMBL91276 | 0.74 | MAPT (0.39) | MAPTL3MBTL1HPGDMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | BEZENCON OLIVIER | 2010-12-23 | — | — | US | disclosed |
| US-20100280024-A1 | RENIN INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2010-11-04 | — | — | US | disclosed |
| US-7799805-B2 | Piperidine carboxylic acid amide derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-2205559-A1 | RENIN INHIBITORS | Cadila Healthcare Limited (IN) | 2010-07-14 | — | — | EP | disclosed |
| WO-2010011584-A2 | PROCESS FOR MAKING A RENIN INHIBITOR | MERCK & CO., INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009087649-A1 | RENIN INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-04-02 | — | — | US | disclosed |
| US-20090062342-A1 | AMINES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-03-05 | — | — | US | disclosed |
| EP-2029542-A2 | PRIMARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2009-03-04 | — | — | EP | disclosed |
| EP-1994026-A2 | NEW AMINES | Actelion Pharmaceuticals Ltd. (CH) | 2008-11-26 | — | — | EP | disclosed |
| EP-1981847-A1 | SECONDARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-09-04 | — | — | US | disclosed |
| EP-1893578-A2 | NOVEL PIPERIDINE CARBOXYLIC ACID AMIDE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007102127-A2 | NEW AMINES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007099509-A2 | PRIMARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007088514-A1 | SECONDARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006129237-A2 | NOVEL PIPERIDINE CARBOXYLIC ACID AMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | REN, ACE, AGTR2 | MAPT 2131/4885L3MBTL1 4883/4885HPGD 429/4885 |
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | REN, ACE, AGTR2 | MAPT 1742/4885L3MBTL1 4883/4885HPGD 494/4885 |
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | REN, ACE, AGTR1 | MAPT 1268/4885L3MBTL1 4878/4885HPGD 490/4885 |
| US-20100280024-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | MAPT 45/4885L3MBTL1 4883/4885HPGD 599/4885 |
| US-20090062342-A1 | AMINES | REN, ACE, MAOA | MAPT 628/4885L3MBTL1 4882/4885HPGD 597/4885 |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | MAPT 1596/4885L3MBTL1 4883/4885HPGD 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.